Industry Symposium at the DGK
07.04.2021
An Industry Symposium about CRP, Lp(a) and Hydration is organized by Pentracor together with Kaneka at the 87th Annual Meeting of the DGK.
07.04.2021
An Industry Symposium about CRP, Lp(a) and Hydration is organized by Pentracor together with Kaneka at the 87th Annual Meeting of the DGK.
20.03.2021
Pentracor organizes a Care Symposium about CRP apheresis at the 13th ISFA & E-ISFA Congress.
30.03.2021
The Brandenburg business magazine FORUM reported on CRP apheresis in its April 2021 issue.
11.03.2021
Results of the first clinical trial of CRP apheresis after acute myocardial infarction (CAMI1) were published in the cardiology journal Frontiers in Cardiovascular Medicine.
"CRP apheresis as anti-inflammatory therapy for acute myocardial infarction: results from the CAMI-1 trial."
The article describes that C-reactive protein substantially triggers myocardial damage after myocardial infarction.
Hennigsdorf, February 17, 2021 - Pentracor GmbH, based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), has achieved a major success with the publication of an article in the renowned immunology journal "Frontiers in Immunology". The title: "C-reactive protein activates cell death in poorly perfused cell tissue". The article, reviewed by the editors and several physicians at Frontiers, can be considered a milestone in the formation of opinion for clinical physicians on the new view of the physiological function of the protein CRP.
10.02.2021
"C-reactive protein triggers cell death in ischemic cells":
In the Research Topic "Diagnostic and Therapeutic Applications of Pentraxin and Pentraxin-Associated Proteins" of the journal Frontiers in Immunology, a review on the pathomechanism of CRP in organ-damaging inflammation was published.
25.01.2021
The page 'Healthcare in Europe' reported about the recently successfully treated COVID-19 patient.
Hennigsdorf, January 27, 2021 - The medical technology company Pentracor GmbH, headquartered in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has successfully treated a patient suffering from COVID-19 caused by the Corona virus with its CE-certified and patent-protected medical product PentraSorb® CRP. The company has thus created another important option for action in the fight against the often fatal effects of the pandemic.
20.01.2021
The Märkische Oderzeitung reported about a recently successfully treated COVID-19 patient. The patient was treated 4 times with CRP apheresis and is recovering rapidly from the disease. The article describes that the therapy most likely saved the patient from intensive care medical treatment.
13.01.2021
The use of CRP apheresis in COVID-19 patients was presented once again in the rbb PRAXIS magazine.
The feature reports the recent successful treatment of a COVID-19 patient with apheresis. In addition, Prof. Dr. Kielstein from the Braunschweig Clinic advocates for the therapy.